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Abstract
Therapies that raise levels of HDL, which is thought to exert atheroprotective effects via effects on
endothelium, are being examined for the treatment or prevention of coronary artery disease (CAD).
However, the endothelial effects of HDL are highly heterogeneous, and the impact of HDL of patients
with CAD on the activation of endothelial eNOS and eNOS-dependent pathways is unknown. Here we
have demonstrated that, in contrast to HDL from healthy subjects, HDL from patients with stable CAD
or an acute coronary syndrome (HDLCAD) does not have endothelial antiinflammatory effects and does
not stimulate endothelial repair because it fails to induce endothelial NO production. Mechanistically,
this was because HDLCAD activated endothelial lectin-like oxidized LDL receptor 1 (LOX-1),
triggering endothelial PKCβII activation, which in turn inhibited eNOS-activating pathways and
eNOS-dependent NO production. We then identified reduced HDL-associated paraoxonase 1 (PON1)
activity as one molecular mechanism leading to the generation of HDL with endothelial
PKCβII-activating properties, at least in part due to increased formation of malondialdehyde in HDL.
Taken together, our data indicate that in patients with CAD, HDL gains endothelial LOX-1- and thereby
PKCβII-activating properties due to reduced HDL-associated PON1 activity, and that this leads to
inhibition of eNOS-activation and the subsequent loss of the endothelial antiinflammatory and
endothelial repair-stimulating effects of HDL.
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Effects of HDLCAD as compared with HDLHealthy 






























Effects of HDLHealthy and HDLCAD on eNOS-activating pathways and 



























Characteristics of the study population
	 Healthy	subjects		 sCAD		 ACS	 P
	 (n	=	25)	 (n	=	25)	 (n	=	25)	
Age (yr) 54 ± 5 56 ± 6 54 ± 6 NS
Sex (male/female) 19/6 19/6 18/7 NS
BMI (kg/m2) 26 ± 5 27 ± 4 26 ± 3 NS
MAP (mmHg) 96.6 ± 6.4 96.4 ± 13.8 96.1 ± 12.8 NS
Fasting glucose (mmol/l) 5.3 ± 1.0 5.4 ± 0.9 5.1 ± 0.7 NS
HbA1c (%) 5.5 ± 0.2 5.4 ± 0.6 5.7 ± 0.9 NS
Total cholesterol (mmol/l) 4.8 ± 0.7 4.3 ± 1.2 4.5 ± 0.6 NS
HDL cholesterol (mmol/l) 1.4 ± 0.4 1.2 ± 0.3 1.2 ± 0.9 NS
LDL cholesterol (mmol/l) 2.9 ± 0.9 2.7 ± 1.0 2.8 ± 0.6 NS
Triglycerides (mmol/l) 1.1 ± 0.4 1.2 ± 0.3 1.1 ± 0.2 NS
CRP (μmol/l) 2.0 ± 1.0 3.0 ± 5.0 4.0 ± 8.0 NS
Creatinine (μmol/l) 88.0 ± 9.0 89.0 ± 21.0 84.0 ± 10.0 NS
ASS (%) 0 100 80 0.03
Clopidogrel (%) 0 40 32 NS
ACE-I/ARB (%) 0 68 56 NS
Beta blocker (%) 0 68 52 0.04
Diuretics (%) 0 12 16 NS
Calcium blocker (%) 0 8 8 NS
Statins (%) 0 76 64 NS
CRP, C-reactive protein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type I 
receptor blocker; ASS, acetylsalicylic acid (aspirin).
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Effects of HDL from healthy subjects, patients with sCAD or ACS on endothelial cell NO production, as determined by ESR spectroscopy analysis. 
(A) HDL from healthy subjects and patients with sCAD or ACS was isolated by sequential ultracentrifugation, and the effects of HDL (50 μg/ml) on 
endothelial cell NO production were analyzed by ESR spectroscopy analysis (n = 25 per group). Data are expressed as percent change versus 
buffer-treated cells; data points for each study participant are shown. (B) Representative ESR spectra of the NO-Fe(DETC)2 signal in endothelial 
cells treated with HDL from healthy subjects and patients with sCAD or ACS. (C) Increasing physiological concentrations of HDL (25, 50, and 100 
μg/ml) from healthy subjects stimulated endothelial NO production that was not observed with increasing concentrations of HDL from patients with 
sCAD or ACS (n = 12 per group). (D) Effects of HDL2 (d = 1.063–1.125 g/ml) and HDL3 (d = 1.125–1.21 g/ml) from patients with sCAD or ACS and 
healthy subjects, separated by sequential ultracentrifugation, on endothelial cell NO production (n = 12–15 per group).
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Figure 
Effects of HDL from healthy subjects and patients with sCAD and ACS on endothelial Akt activation, eNOS-activating/inhibiting phosphoryla-
tion, and endothelial superoxide production. (A) Effects of HDL (50 μg/ml) on phosphorylation of Akt at Ser473, (B) Akt-dependent activating 
phosphorylation of eNOS at Ser1177, and (C) inhibitory phosphorylation of eNOS at Thr495 in HAECs, as detected by Western blot analysis (n = 
10–12 per group). (D) Effects of HDL on endothelial superoxide production (n = 25 per group; data points for all study participants are shown) and 
(E) NAD(P)H oxidase activity, as measured by ESR spectroscopy (n = 8–10 per group). (F) Representative ESR spectra of NAD(P)H oxidase 
activity in HAECs treated with buffer (basal) and with HDL from healthy subjects or patients with sCAD or ACS.
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Critical role of eNOS in the effects of HDL on TNF-a–stimulated endothelial NF-kB activation and VCAM-1 expression. (A) Inhibition of eNOS-
mediated endothelial NO production by siRNA knockdown of eNOS or treatment with L-NAME (1 mM) prevented the effects of HDL (50 μg/ml) 
from healthy subjects on endothelial NF-kB activation (as examined by TNF-a–stimulated DNA binding of NF-kB subunit p65; n = 8–10 per 
group). Scr., scrambled. (B) In contrast to HDL from healthy subjects, HDL from patients with sCAD and ACS failed to inhibit TNF-a–stimulated 
endothelial NF-kB activation (n = 10–12 per group). (C) Representative images (original magnification, ×20) showing that HDL from a healthy 
subject, but not from patients with sCAD or ACS, inhibited endothelial nuclear translocation of NF-kB subunit p65, as detected by fluorescence 
microscopy of TNF-a–stimulated HAECs. (D) Inhibition of eNOS-mediated NO production by siRNA knockdown of eNOS or treatment with 
L-NAME prevented the effects of HDL from healthy subjects on TNF-a–stimulated VCAM-1 expression in HAECs, as detected by Western blot 
analysis (n = 8–10 per group). (E) Effect of HDL from healthy subjects and patients with sCAD or ACS on TNF-a–stimulated VCAM-1 expression 
in HAECs (n = 25 per group; data points for all study participants are shown).
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Effects of HDLCAD and HDLHealthy on endothelial PKCβII phosphory-
lation and its impact on eNOS-activating pathways — role of endothelial 
LOX-1 receptor. Our observation that HDL from patients with CAD 
Figure 
Role of eNOS for the effects of HDL 
on TNF-a–stimulated endothelial 
monocyte adhesion. (A) Inhibition of 
eNOS-mediated NO production by 
siRNA-specific knockdown of eNOS 
or treatment with L-NAME (1 mM) 
prevented the potent inhibitory effects 
of HDL from healthy subjects on 
endothelial cell monocyte adhesion 
(n = 6–8 per group). Endothelial cells 
were incubated with HDL (50 μg/ml) 
from healthy subjects, and binding 
of CFSE-labeled human monocytes 
was analyzed after 3 hours by fluo-
rescence microscopy (HAECs were 
stimulated with TNF-a; 5 ng/ml). (B) 
Representative photographs (origi-
nal magnification, ×10) of endothelial 
monocyte adhesion obtained by fluo-
rescence microscopy are shown. (C) 
Effects of HDL isolated from patients 
with sCAD and ACS as compared 
with HDL from healthy subjects on 
TNF-a–stimulated endothelial mono-
cyte adhesion (n = 25 per group; 
data points for all study participants 
are shown).
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Notably,  the protein-bound MDA content was  increased  in 
Figure 
Impaired endothelial repair capacity and specific endothelial binding of HDL from patients with sCAD or ACS as compared with healthy subjects. 
(A) HDL from healthy subjects and patients with sCAD or ACS was injected in nude mice following carotid artery injury, and re-endothelialized 
area was determined after 3 days by staining with Evan’s blue (n = 6–8 per group). (B) Representative photographs of carotid arteries from nude 
mice stained with Evan’s blue. (C) HDL from healthy subjects and patients with sCAD or ACS was labeled with sodium iodide I-125, and binding 
of 125I-HDL to endothelial cells was examined (n = 8–10 per group). (D) Effect of siRNA-specific knockdown of SR-BI on endothelial binding of 
HDL from healthy subjects and patients with CAD (n = 4–5 per group).
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Differential effects of HDL from healthy subjects and patients with sCAD or ACS on endothelial LOX-1 and PKCβII activation — role of PKCβII 
activation in the altered effects of HDL on endothelial Akt and eNOS-activating/inhibiting phosphorylation in patients with CAD. (A) Effect of HDL 
from healthy subjects and patients with sCAD and ACS on PKCβII-activating phosphorylation at Ser660 and (B) membrane translocation of 
PKCβII in endothelial cells (n = 8–12 per group). (C) Incubation of endothelial cells with the nonselective inhibitor of PKCβI and PKCβII isoforms 
LY379196 and CGP53353, a highly selective inhibitor of PKCβII, restored the ability of HDL from patients with CAD to stimulate endothelial NO 
production and (D) the activating eNOS phosphorylation at Ser1177 (n = 8–10 per group). (E) Pretreatment of endothelial cells with an anti–LOX-1 
blocking antibody prevented the increase in PKCβII phosphorylation at Ser660 (n = 6–8 per group). (F) Moreover, incubation of endothelial 
cells with an anti–LOX-1 blocking antibody improved the capacity of HDL from patients with CAD, but not from healthy subjects, to stimulate 
endothelial NO production (n = 8–10 per group).
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Critical role of HDL-associated MDA in the impaired capacity of HDL to increase endothelial NO production and in the increased stimulation of 
PKCβII by HDL. (A) Protein-bound MDA content in HDL from healthy subjects and patients with sCAD or ACS was measured by spectrophotom-
etry, as described in more detail in Methods (n = 12–14 per group). (B) Mass spectrometry analysis of MDA-lysine adducts in HDL from healthy 
subjects and patients with CAD (n = 4 per group). (C) Effect of MDA-modified HDL on endothelial NO production, as measured by ESR spectros-
copy (n = 8 per group). (D) Inhibition of endothelial LOX-1 with a specific blocking antibody partially prevented the decrease in endothelial NO 
production in response to MDA-modified HDL (12.5 mol MDA/mol apoA-I; n = 6 per group). (E) Modification of HDL by MDA (12.5 mol MDA/mol 
apoA-I; n = 6 per group) resulted in an increased activation of endothelial PKCβII that was prevented by a specific blocking antibody against 
endothelial LOX-1 (n = 6–10 per group).
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Effect of HDL from Pon1-deficient mice on endothelial NO production, 


















Activity and content of HDL-associated PON1 in healthy subjects and patients with sCAD or ACS — effect of inhibition of PON1 on HDL-associ-
ated MDA content and phosphorylation of PKCβII at Ser660. (A) Paraoxonase and (B) arylesterase activities of HDL-associated PON1 isolated 
from healthy subjects and patients with sCAD or ACS, as measured by UV spectrophotometry (n = 25 per group). (C) PON1 content in HDL 
isolated from healthy subjects and patients with sCAD or ACS was determined by Western blot analysis (n = 25 per group). (D) Effect of the 
specific PON1 inhibitor hydroxyquinoline (HQ, 200 μM) on protein-bound MDA content and (E) MDA-lysine adducts in HDL, as detected by 
spectrophotometry and mass-spectrometry analysis, respectively (n = 4–6 per group). (F) Effect of HDL pretreated with the PON1 inhibitors HQ 
or EDTA (5 mM) on phosphorylation of PKCβII at Ser660 was detected by Western blot analysis (n = 8–10 per group).
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Effect of inhibition of HDL-associated PON1 on eNOS-activating signaling pathways, endothelial cell NO production, endothelial cell inflammatory 
activation, and endothelial repair. Effect of supplementation of HDL from CAD patients with recombinant PON1 on the capacity of HDL to stimu-
late endothelial NO production. (A) HDL-associated PON1 was inhibited either by hydroxyquinoline (200 μM) or EDTA (5 mM), and the effect 
of HDL on the activating eNOS phosphorylation at Ser1177 and (B) the inhibitory eNOS phosphorylation at Thr495 was examined by Western 
blot analysis (n = 6–7 per group). (C) Inhibition of HDL-associated PON1 resulted in a loss of the capacity of HDL to stimulate endothelial NO 
production, as measured by ESR spectroscopy (n = 6–8 per group). (D) Furthermore, treatment of HDL from healthy subjects with PON1 inhibi-
tors impaired the capacity of HDL to inhibit TNF-a–stimulated endothelial monocyte adhesion (n = 8–10 per group). (E) Importantly, inhibition 
of PON1 in HDL from healthy subjects prevented stimulation of endothelial repair after carotid artery injury in nude mice (n = 6 per group). (F) 
Supplementation of HDL from patients with CAD with purified PON1 (pPON1; 5 U/100 μg HDL protein) partially restored the capacity of HDL to 
stimulate endothelial NO production as measured by ESR spectroscopy (n = 6–9 per group).
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endothelial NO production  is  related  to  endothelial LOX-1–
Figure 0
Effects of HDL isolated from Pon1-deficient mice or their wild-type littermates on endothelial cell NO production, superoxide production, and 
endothelial inflammatory activation. (A) In contrast to HDL from wild-type littermates, HDL isolated from Pon1-deficient mice inhibited rather 
than stimulated NO production in mouse aortic endothelial cells, as detected by ESR spectroscopy analysis (n = 5 per group). (B) In addition, 
HDL from Pon1-deficient mice failed to inhibit basal and TNF-a–stimulated superoxide production in mouse aortic endothelial cells (ESR spec-
troscopy analysis, n = 5–7 per group). (C) Whereas HDL from wild-type littermates potently inhibited endothelial inflammatory activation, HDL 
from Pon1-deficient mice did not inhibit TNF-a–stimulated VCAM-1 expression and (D) endothelial monocyte adhesion (n = 5–6 per group). 
(E) Supplementation of HDL from Pon1-deficient mice with purified PON1 (5 U/100 μg HDL protein) partially restored the capacity of HDL to 
stimulate endothelial NO production as measured by ESR spectroscopy (n = 5–6 per group).
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Detection of nuclear translocation of the NF-kB subunit RelA/p65 by immuno-



























Binding of HDL to endothelial cells. Binding of HDL to HAECs was exam-
ined as described in detail previously (36, 44). Further details are provided 
in Supplemental Methods.
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